Bell S G
Neonatal Netw. 1996 Sep;15(6):13-8.
The widespread use of indwelling intravascular catheters, such as central venous lines and umbilical vessel catheters, has resulted in an increased number of thrombotic complications and subsequently a growing need for specific thrombolytic therapy. The use of thrombolytic agents that have a high incidence of systemic fibrinolysis is of concern, however, especially in premature neonates. Tissue plasminogen activator is a locally acting thrombolytic agent that occurs naturally in the body. Tissue plasminogen activator can now be mass-produced through recombinant DNA technology. Reports of recombinant tissue plasminogen activator use in neonates are beginning to appear in the literature. This thrombolytic agent appears to be promising for the local lysis of clots within systemic coagulopathy. However, there is a need for controlled studies of thrombolytic agents in the neonatal population.
留置血管内导管（如中心静脉导管和脐血管导管）的广泛使用，导致血栓形成并发症的数量增加，进而对特定溶栓治疗的需求日益增长。然而，全身纤溶发生率高的溶栓药物的使用令人担忧，尤其是在早产儿中。组织型纤溶酶原激活剂是一种在体内天然存在的局部作用溶栓剂。现在可以通过重组DNA技术大量生产组织型纤溶酶原激活剂。关于重组组织型纤溶酶原激活剂在新生儿中使用的报告开始出现在文献中。这种溶栓剂似乎有望用于全身性凝血病中血栓的局部溶解。然而，需要对新生儿群体中的溶栓剂进行对照研究。
